Previous Close | 1.0500 |
Open | 1.0800 |
Bid | 1.0100 x 800 |
Ask | 1.0400 x 1000 |
Day's Range | 1.0501 - 1.2400 |
52 Week Range | 0.8900 - 2.3300 |
Volume | |
Avg. Volume | 118,080 |
Market Cap | 11.145M |
Beta (5Y Monthly) | 0.90 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.1600 |
Earnings Date | Feb 08, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 8.55 |
Subscribe to Yahoo Finance Plus to view Fair Value for ONVO
Organovo Holdings ( NASDAQ:ONVO ) Third Quarter 2024 Results Key Financial Results Net loss: US$3.60m (loss widened by...
By Brad Sorensen, CFA NASDAQ:ONVO READ THE FULL ONVO RESEARCH REPORT Organovo (NASDAQ:ONVO) reported its fiscal 3Q earnings and results were roughly inline with our expectations and illustrate to us that the company continues to progress toward bringing important products to market. Specifically, the company reported: • Earnings of -$0.40 per share, inline with estimates as expenses remained
SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical stage biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis, based on demonstration of clinical promise in three-dimensional (3D) human tissues, today announced the presentation of preclinical data related to the company’s FXR314 development program in its proprietary 3D human tissue models of Crohn’s disease and ulcerative colitis at the